Give Patients With Diabetes a Safety Net
Gvoke HypoPen® is the ready-to-use glucagon autoinjector patients can count on to bring very low blood glucose levels back up quickly and safely1†
Store in original sealed pouch until time of use.
Guidelines recommend ready-to-use glucagon
Glucagon is underutilized and under-prescribed
Patients don’t have glucagon when they need it
Ensure Patients Are Ready To Treat Severe Lows
Diabetes guidelines acknowledge that:
- Patients taking insulin or sulfonyulreas are at increased risk for hypoglycemia2,7
- Patients taking insulin or sulfonylureas should have a prescription for ready-to-use glucagon2
But glucagon prescriptions are not aligned with guideline recommendations: An estimated 8% of patients taking insulin receive a glucagon prescription.3-5 This leaves around 8 million patients who are clinically appropriate for glucagon without a safety net for severe hypoglycemia.
What Healthcare Providers Say About Gvoke HypoPen
† In a pooled analysis of 2 clinical studies in adults, mean time to treatment success was 13.8 minutes with treatment success defined as plasma glucose increase from mean value (< 50 mg/dL) at time of glucagon administration to absolute value greater than 70 mg/dL or relative increase of 20 mg/dL or greater.
‡ Results from an online survey in adults with self-reported type 1 (n=110) or type 2 (n=109) diabetes treated with insulin who experienced a recent severe hypoglycemic event (in the past 3 years).
*Offer not valid for prescriptions reimbursed under Medicaid, a Medicare drug benefit plan, TRICARE, or other federal or state health programs (such as medical assistance programs).
- Gvoke HypoPen [prescribing information]. Chicago, IL: Xeris Pharmaceuticals, Inc; 2023.
- McCall AL, Lieb DC, Gianchandani R, et al. Management of individuals with diabetes at high risk for hypoglycemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2023;108(3):529-562.doi:10.1210/clinem/dgac596
- American Diabetes Association. Fast Facts 2022. Accessed January 11, 2023. https://professional.diabetes.org/content/fast-facts-data-and-statistics-about-diabetes
- American Diabetes Association. Fast Facts 2020. Accessed January 11, 2023. https://professional.diabetes.org/sites/professional.diabetes.org/files/media/sci_2020_diabetes_fast_facts_sheet_final.pdf
- Data on file. Xeris Pharmaceuticals, Inc.
- Snoek FJ, Spaepen E, Nambu BA, et al. Conversations and Reactions Around Severe Hypoglycemia (CRASH) Study: Results From People With Diabetes and Caregivers in the United States. Clin Diabetes. 2022;40(4):477-488. doi:10.2337/cd21-0131
- ElSayed NA, Aleppo G, Aroda VR, et al. 6. Glycemic Targets: Standards of Care in Diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S97-S110. doi:10.2337/dc23-S006
INDICATION AND IMPORTANT SAFETY INFORMATION
GVOKE is indicated for the treatment of severe hypoglycemia in adult and pediatric patients with diabetes ages 2 years and above.
IMPORTANT SAFETY INFORMATION
GVOKE is contraindicated in patients with pheochromocytoma because of the risk of substantial increase in blood pressure, insulinoma because of the risk of hypoglycemia, and known hypersensitivity to glucagon or to any of the excipients in GVOKE. Allergic reactions have been reported with glucagon and include anaphylactic shock with breathing difficulties and hypotension.
Warnings and Precautions
GVOKE is contraindicated in patients with pheochromocytoma because glucagon may stimulate the release of catecholamines from the tumor. If the patient develops a dramatic increase in blood pressure and a previously undiagnosed pheochromocytoma is suspected, 5 to 10 mg of phentolamine mesylate, administered intravenously, has been shown to be effective in lowering blood pressure.
In patients with insulinoma, administration of glucagon may produce an initial increase in blood glucose; however, GVOKE administration may directly or indirectly (through an initial rise in blood glucose) stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. GVOKE is contraindicated in patients with insulinoma. If a patient develops symptoms of hypoglycemia after a dose of GVOKE, give glucose orally or intravenously.
Allergic reactions have been reported with glucagon. These include generalized rash, and in some cases, anaphylactic shock with breathing difficulties and hypotension. GVOKE is contraindicated in patients with a prior hypersensitivity reaction.
GVOKE is effective in treating hypoglycemia only if sufficient hepatic glycogen is present. Patients in states of starvation, with adrenal insufficiency or chronic hypoglycemia, may not have adequate levels of hepatic glycogen for GVOKE administration to be effective. Patients with these conditions should be treated with glucose.
Necrolytic migratory erythema (NME), a skin rash commonly associated with glucagonomas (glucagon-producing tumors) and characterized by scaly, pruritic erythematous plaques, bullae, and erosions, has been reported postmarketing following continuous glucagon infusion. NME lesions may affect the face, groin, perineum and legs or be more widespread. In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. Should NME occur, consider whether the benefits of continuous glucagon infusion outweigh the risks.
Most common (≥5%) adverse reactions associated with GVOKE are nausea, vomiting, injection site edema (raised 1 mm or greater), and hypoglycemia.
Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE. In patients taking indomethacin, GVOKE may lose its ability to raise blood glucose or may even produce hypoglycemia. GVOKE may increase the anticoagulant effect of warfarin.
Please see the Full Prescribing Information for Gvoke.